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Introduction
Antiretroviral drug-related liver injury is a common
cause of morbidity and treatment discontinuation in
HIV-infected patients. Nevirapine is incriminated as one
of the liver toxicity inducer especially in patients with
high CD4-cells count. The purpose of our study was to
analyze the role of CD4 cell count at treatment initiation
and that of several co-factors (Hepatitis C or Hepatitis B
virus co-infection, concurrent use of protease inhibitors)
on the incidence of liver toxicity and hypersensivity reac-
tions induced by Nevirapine in our HIV1-infected
patients.
Material and method
We analyzed retrospectively a cohort of 930 HIV-1
infected patients. Patients, who were started on NVP
between 1998 and 2003, regardless of CD4-cells count,
were included. We assigned patients to two groups: (A)
group with high CD4-cells counts (women with CD4 cells
≥ 250 cells/mm³ and men with ≥ 400 cells/mm³), and (B)
group with low CD4-cell counts. Liver toxicity is consid-
ered severe when at least a grade 3 toxicity is observed
(WHO classification).
Results
In total 108 patients were included. Eight (7.40%) and 15
(13.9%) patients interrupted treatment because of severe
liver toxicity and hypersensitivity reactions respectively.
There was no overlap between these two groups, and
hypersensitivity reactions tended to occur sooner (22 vs 45
days respectively). HCV and HBV co-infection rates were
7.4% and 8.33%. Severe liver toxicity was seen in 15.74% of
patients. Comparing group A and B, rates of severe liver
toxicity were 15.68% and 17.30% respectively. There was
no significant difference. In a multiple linear regression
model, we found viral hepatitis C co-infection to be the
only independent risk factor in the occurrence of liver
toxicity (p<0.006).
Conclusion
In our study the rate of severe liver toxicity due to NVP
was high. HCV co-infection was an independent risk
factor for liver toxicity, contrary to CD4 cell counts at
treatment initiation. These findings are in keeping with
recent published data. A careful analysis of the literature
shows that hypersensitivity reactions due to NVP are
strongly correlated with high CD4 cell counts. The lim-
itation of our study is the low number of patients
included.
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